SCHEMBL3268239

SCHEMBL3268239

Cc1ccc2c(=O)c3cccc(Br)c3oc2c1C

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GLA P06280 1/20 0.58
▸ STING1 Q86WV6 1/20 0.58
▸ MCL1 Q07820 1/20 0.41
▸ PON1 P27169 1/20 0.41
▸ NQO1 P15559 1/20 0.41
▸ ATP1A1 P05023 2/20 0.41
▸ ATP1B1 P05026 2/20 0.41
▸ ATP1A3 P13637 2/20 0.41
▸ ATP1B2 P14415 2/20 0.41
▸ ATP1A2 P50993 2/20 0.41
▸ ATP1B3 P54709 2/20 0.41
▸ FXYD2 P54710 2/20 0.41
▸ ATP1A4 Q13733 2/20 0.41
▸ LOXL2 Q9Y4K0 1/20 0.40
▸ ESR2 Q92731 5/20 0.39
▸ ESR1 P03372 2/20 0.38
▸ MEN1 O00255 3/20 0.37
▸ KMT2A Q03164 3/20 0.37
▸ NPC1 O15118 2/20 0.37
▸ RAB9A P51151 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13395991 0.85 GLA (0.62) GLASTING1MCL1PON1NQO1
SCHEMBL15678569 0.84 LOXL2 (0.50) GLASTING1ATP1A1ATP1B1ATP1A3
SCHEMBL3267026 0.81 ESR2 (0.47) GLASTING1MCL1PON1NQO1
SCHEMBL9378856 0.81 LOXL2 (0.40) GLASTING1ATP1A1ATP1B1ATP1A3
SCHEMBL28469112 0.81 GLA (0.58) GLASTING1MCL1PON1NQO1
SCHEMBL3271856 0.80 LOXL2 (0.40) GLASTING1ATP1A1ATP1B1ATP1A3
SCHEMBL12422074 0.79 GLA (0.72) GLASTING1MCL1PON1NQO1
SCHEMBL23900884 0.78 GLA (0.75) GLASTING1MCL1PON1NQO1
SCHEMBL1324122 0.77 PTGS2 (0.57) GLASTING1MEN1KMT2ANPC1
SCHEMBL29398254 0.77 PTGS2 (0.57) GLASTING1MEN1KMT2ANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8350065-B2 5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same GRAND PHARMA (CHINA) CO., LTD. (CN) 2013-01-08 — — US disclosed
US-8350065-B2 5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same GRAND PHARMA (CHINA) CO., LTD. (CN) 2013-01-08 — — US disclosed
US-8350065-B2 5,6-dimethyl xanthone-4-acetic acid derivatives and method of preparing the same GRAND PHARMA (CHINA) CO., LTD. (CN) 2013-01-08 — — US disclosed
CN-101195609-B Method for producing 5,6-dimethyl xanthenone-4-acetic acid, derivant and pharmaceutical formulation produced with the method WUHAN GRAND PHARMACEUTICAL GROUP CO LTD 2011-04-20 — — CN disclosed
EP-2196463-A1 PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, THE DERIVATIVES PREPARED AND PHARMACEUTICAL FORMULATIONS THEREOF Wuhan Grand Pharmaceutical Group Co., Ltd (CN) 2010-06-16 — — EP disclosed
EP-2196463-A1 PREPARATION OF 5,6-DIMETHYLXANTHONE-4-ACETIC ACID, THE DERIVATIVES PREPARED AND PHARMACEUTICAL FORMULATIONS THEREOF Wuhan Grand Pharmaceutical Group Co., Ltd (CN) 2010-06-16 — — EP disclosed
US-20100099754-A1 5,6-DIMETHYL XANTHONE-4-ACETIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME GRAND PHARMA (CHINA) CO., LTD. (CN) 2010-04-22 — — US disclosed
US-20100099754-A1 5,6-DIMETHYL XANTHONE-4-ACETIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME GRAND PHARMA (CHINA) CO., LTD. (CN) 2010-04-22 — — US disclosed
US-20100099754-A1 5,6-DIMETHYL XANTHONE-4-ACETIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME GRAND PHARMA (CHINA) CO., LTD. (CN) 2010-04-22 — — US disclosed
CN-101195609-A Method for producing 5,6-dimethyl xanthenone-4-acetic acid, derivant and pharmaceutical formulation produced with the method WUHAN YUANDA PHARMACY GROUP CO (CN) 2008-06-11 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100099754-A1 5,6-DIMETHYL XANTHONE-4-ACETIC ACID DERIVATIVES AND METHOD OF PREPARING THE SAME HCAR2, HAO2, HK2 GLA 2459/4885STING1 2933/4885MCL1 2403/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback